Daratumumab in STK11 Mutated NSCLC
NCT05807048
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
8
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
Interventions
DRUG:
Daratumumab and Hyaluronidase-fihj
DRUG:
Pre-Intervention Medication
DRUG:
Post-Intervention Medication
Sponsor
NYU Langone Health